AbCellera Biologics Inc. (ABCL)
- Sector
- Life Sciences Tools & Services
- Last price
- $11.03
- As of
Kresmion compiles this page from ABCL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AbCellera Biologics Inc. (ABCL): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full ABCL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABCL on one page. Preview it with sample data, then open it live with a free account.
Preview the ABCL dossierActive events for ABCL
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 53% of ABCL (2026Q3)
- medium13F: new position
SOROS FUND MANAGEMENT LLC new position in ABCL
- mediumEarnings above estimates
Q3-2026: Beat consensus by 24.2%, EPS $-0.13 vs $-0.1714 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +113% to ABCL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +351% to ABCL (2026Q2)
FREE, NO ACCOUNT
Every event on ABCL, as it fires
You are seeing 5 of 9 events recorded on ABCL since 2026-07-24.
The five above landed across 3 days. The other 4 were recorded on 2 other days. 7 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ABCL positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 00288U106 · 2026Q3 | $6.7M | 0.01% |
| SOROS FUND MANAGEMENT LLC FundCUSIP 00288U106 · 2026Q3 | $2.2M | 0.03% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABCL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on ABCL
ABCL against its peers
ABCL's operating margin of -289.0% ranks in the 15th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | ABCL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 75.1M USD | 1.2B USD | 17 | 25 |
| Gross margin | n/a | 55.5% | n/a | 17 |
| Operating margin | -289.0% | -9.5% | 15 | 23 |
| Net margin | -194.9% | -6.8% | 17 | 25 |
| Return on equity | -15.1% | -7.5% | 46 | 24 |
| P / E | n/a | 42.4x | n/a | 9 |
| 1 year | 208.0% | 22.5% | 94 | 25 |
Peers (25): ADPT, SHC, FTRE, TXG, BRKR, AVTR, RGEN, MRVI, TECH, TEM, CRL, MLAB, CTKB, MEDP, OABI, DNA, PACB, ILMN, MTD, IQV, A, WAT, CDXS, MXCT, SEER. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ABCL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ABCL on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ABCL in the last 180 days.
Upstream: SEC EDGAR filings for ABCL
Kresmion, "AbCellera Biologics Inc. (ABCL) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/ABCL. Upstream data: SEC EDGAR filings for ABCL.
Link to this data (HTML):
<a href="https://kresmion.com/research/ABCL">AbCellera Biologics Inc. (ABCL) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ABCL on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ABCL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.